Article preview reprinted from IN VIVO -December 2008
Arbor Vita (protein-based diagnostics and therapeutics) has chosen Becton Dickinson to help it develop a new diagnostic for cervical cancer.
Deals Shaping the Medical Industry
Article preview reprinted from IN VIVO -December 2008
Arbor Vita's work on diagnostics focuses on PDZ proteins, also known as cellular organizers in the body's signaling pathways. The company has discovered that detecting PDZ proteins and their binding ligands can be a strong indicator of pathogens and proteins which are overexpressed in certain diseases. BD and Arbor Vita will work together on Arbor Vita's AVC Dx1, a PDZ-based test that detects the E6 protein produced by HPV, a precursor to cervical cancer. (Arbor Vita is also developing another version of this diagnostic on its own that will be used in developing countries and funded by the National Cancer Institute.)
Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed. Subscribe to IN VIVO.
IN VIVO delivers:
- Revealing, in-depth coverage of your competitors' strategies
- Incisive projections of future industry trends and their implications for your business
- Expert analysis of key industry developments
- Exclusive interviews with top industry executives and analysts
- In-depth examination of dealmaking, marketing, R&D, regulatory, and finance strategies -- those that were successful and those that missed the mark
- Subscribe to IN VIVO today!
